Using a new mathematical model, researchers uncovered mutational signatures related to homologous recombination deficiency in up to one-fifth of breast cancers.
The combination test will allow clinicians to analyze breast cancer patients for germline hereditary cancer markers at the same time as they search their blood for driver mutations.
Based on survey responses from more than 2,500 women with breast cancer, researchers reported a robust demand for genetic testing and counseling.
While Angelina Jolie's op-ed on her BRCA test prompted others to seek testing, many of the women who did had a lower pre-test probability of carrying a mutation, a new study says.
Invitae will test 1,000 breast cancer patients from TME practices using its hereditary cancer test, regardless of whether they meet current eligibility criteria.
The new assay, called the CellMax-DNA Genetic Cancer Risk Test, will complement CellMax Life's planned slate of liquid biopsy assays for early cancer detection.
The molecular diagnostics firm said it will submit its BRACAnalysis CDx alongside AstraZeneca's Lynparza to Japan's Pharmaceuticals and Medical Devices Agency.
A Counsyl study suggests that just half of individuals go through with insurance-mandated pretest genetic counseling, paying out of pocket or canceling the test instead.
Genetic testing can help guide prevention, establish a diagnosis, and choose treatment approaches for breast cancer, the Journal News says.
At Wired, a science journalist discusses her decision not to undergo BRCA testing.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.